Marcelo Bigal, M.D., Ph.D.
Chief Medical Officer, Purdue Pharma
Friday, Nov. 16, 2018 • 10:30 AM–12:00 PM
Marcelo Bigal, MD, PhD was named Purdue Pharma L.P.’s resident Chief Medical Officer (CMO) in March 2018. A member of Purdue’s Executive Committee, Dr. Bigal is responsible for oversight of patient safety and medical governance related to products in development and in the market, as well as addressing the scientific and medical aspects of the company’s product portfolio.
Dr. Bigal brings over 12 years of pharmaceutical experience to his role at Purdue, ranging from research and development, clinical operations and innovations, and scientific affairs. Previously, Dr. Bigal was Chief Scientific Officer at Teva Pharmaceuticals, where he began his tenure as Head of the Clinical Development organization, in which he oversaw Innovative Clinical Development (Phases 1 to 3) across all specialty areas. He later went to become CMO. He was also CMO at Labrys Biologics Inc, overseeing the development of Fremanezumab, a monoclonal antibody for the treatment of migraine headaches. Before that, he served as Global Executive Director at Merck Inc. where he was responsible for Phase IV studies and Investigator Initiated Studies across therapeutic areas. Prior to joining the pharmaceutical industry, Dr. Bigal was a faculty member at the Albert Einstein College of Medicine, Department of Neurology.
Dr. Bigal’s research has earned several prestigious awards, including the American Academy of Neurology Harold Wolff-John Graham Award for outstanding achievements in pain research (2005), The American Headache Society’s Kaplan award for best research in chronic daily headache (twice, in 2004 and 2005), and The American Headache Society’s Harold G. Wolff Award (2008).
Dr. Bigal has published more than 310 peer-reviewed articles in indexed journals and authored or co-authored 35 book chapters.
Dr. Bigal earned a Medical Doctorate degree and a Masters in Science and PhD in Neurosciences from the College of Medicine at the University of São Paulo, Brazil, and completed his post-doctoral research at the New England Center for Headache in Stamford, Connecticut.